X
29.40
-1.31 (-4.27%)
| Previous Close | 30.71 |
| Open | 29.71 |
| Volume | 681,839 |
| Avg. Volume (3M) | 484,034 |
| Market Cap | 2,250,358,272 |
| Price / Sales | 404.48 |
| Price / Book | 4.70 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -969.84% |
| Diluted EPS (TTM) | -3.22 |
| Total Debt/Equity (MRQ) | 1.23% |
| Current Ratio (MRQ) | 17.66 |
| Operating Cash Flow (TTM) | -196.85 M |
| Levered Free Cash Flow (TTM) | -128.49 M |
| Return on Assets (TTM) | -22.03% |
| Return on Equity (TTM) | -31.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Xenon Pharmaceuticals Inc. | Mixed | Bearish |
AIStockmoo Score
2.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 0.14% |
| % Held by Institutions | 103.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (Chardan Capital, 87.08%) | Buy |
| 55.00 (RBC Capital, 87.08%) | Buy | |
| Median | 55.00 (87.08%) | |
| Low | 43.00 (Wedbush, 46.26%) | Buy |
| Average | 51.00 (73.47%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 35.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 12 Aug 2025 | 55.00 (87.07%) | Buy | 35.99 |
| RBC Capital | 12 Aug 2025 | 55.00 (87.07%) | Buy | 35.99 |
| Wedbush | 12 Aug 2025 | 43.00 (46.26%) | Buy | 35.99 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Aug 2025 | Announcement | Xenon Reports Second Quarter 2025 Financial Results & Business Update |
| 04 Aug 2025 | Announcement | Xenon to Report Q2 2025 Financial Results on August 11, 2025 |
| 27 Jun 2025 | Announcement | Xenon Joins the Russell 3000® and Russell 2000® Indexes |
| 26 Jun 2025 | Announcement | Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 24 Jun 2025 | Announcement | Xenon Announces Appointment of Darren Cline as Chief Commercial Officer |
| 03 Jun 2025 | Announcement | Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |